Terray Therapeutics, a biotechnology company using artificial intelligence to accelerate the development of small-molecule drugs, said today it has raised $120 million in a Series B fundraise to ...

While biopharmaceutical technologies have made substantial strides in treating diseases, drug research and development continue to face a multitude of obstacles, such as complex methodologies, high ...

While large-molecule therapeutics capture most headlines, small-molecule drugs face significant challenges, struggling with funding cuts, supply chain disruptions, and growing demand. At the same time ...

Small molecule drugs dominate new drug approvals and are crucial for treating diverse diseases. They are typically low-weight, providing easy absorption and versatile delivery methods. Their simpler ...

GSK said it is ending the development program for the small-molecule drug Belrestotug. The British pharmaceutical giant said Tuesday that the decision is based on a new interim analyses from phase 2 ...